The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global biodefense market reached a value of US$ 12.7 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 6% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Biodefense can be defined as the activity of preparing for, responding to and countering the acts of bioterrorism. A bioterrorism attack involves the deliberate release of bacteria, viruses and other pathogens that can cause chronic illnesses to humans, animals, agriculture and the environment. Biodefense involves various medical measures that are undertaken to protect individuals against biological threats, such as administering vaccinations and medicinal drugs, along with conducting research and various public health procedures. Biodefense products are commonly effective against anthrax, smallpox, botulism, radiation/nuclear disasters and other such catastrophes.
The growing threat of terrorism, coupled with continually rising tension between nations across the globe, is one of the key factors driving the growth of the market. Furthermore, the increasing defense expenditure by the governments of several nations to improve both internal and external security is also providing a boost to the market growth. In line with this, there is widespread adoption of innovative technologies, such as gene chips, for the detection of pathogens in the fields of nanotechnology, forensics and biodefense-related drug development. Additionally, government agencies are recognizing various chemical, biological, nuclear and radiological threats and are developing medical countermeasures to minimize the adverse effects of these attacks. Apart from this, there is an increasing awareness regarding synthetic biology for improving agricultural yields, which is also creating a positive impact on the market growth. Apart from these, due to the recent COVID-19 pandemic, there has been an increasing demand for medical measures and threat detection procedures, which is also providing a boost to the market growth. Other factors, including extensive research and development (R&D) in the field of biotechnology, along with the availability of advanced biothreat detection devices, are projected to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global biodefense market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on vaccine type, biothreat detection device and end-user.
Breakup by Vaccine Type:
Breakup by Biothreat Detection Device:
Breakup by End-User:
Breakup by Region:
The competitive landscape of the industry has also been examined with some of the key players being Achaogen Inc., Alnylam Pharmaceuticals Inc., Altimmune Inc. (PharmAthene Inc.), Bavarian Nordic A/S, Cleveland BioLabs Inc., Dynavax Technologies Corporation, Dynport Vaccine Company LLC (General Dynamics Corporation), Elusys Therapeutics Inc., Emergent Biosolutions Inc., Ichor Medical Systems Inc., Ology Bioservices Inc., SIGA Technologies, Inc., etc.
|Base Year of the Analysis||2020|
|Segment Coverage||Vaccine Type, Biothreat Detection Device, End-User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Achaogen Inc., Alnylam Pharmaceuticals Inc., Altimmune Inc. (PharmAthene Inc.), Bavarian Nordic A/S, Cleveland BioLabs Inc., Dynavax Technologies Corporation, Dynport Vaccine Company LLC (General Dynamics Corporation), Elusys Therapeutics Inc., Emergent Biosolutions Inc., Ichor Medical Systems Inc., Ology Bioservices Inc. and SIGA Technologies, Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
We expect the global biodefense market to exhibit a CAGR of around 6% during 2021-2026.
The growing number of terrorist attacks, along with rising cross-border conflicts, are some of the key factors driving the global biodefense market.
Sudden outbreak of the COVID-19 pandemic has positively influenced the demand for medical measures and threat detection procedures, such as biodefense.
Based on the vaccine type, the global biodefense market has been bifurcated into anthrax, smallpox, botulism, and others. Currently, anthrax holds the majority of the total market share.
Based on the end-user, the global biodefense market can be segmented into hospitals and clinics, ambulatory care centers, and others. Among these, hospitals and clinics exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America dominates the global market.
Some of the major players in the global biodefense market include Achaogen Inc., Alnylam Pharmaceuticals Inc., Altimmune Inc. (PharmAthene Inc.), Bavarian Nordic A/S, Cleveland BioLabs Inc., Dynavax Technologies Corporation, Dynport Vaccine Company LLC (General Dynamics Corporation), Elusys Therapeutics Inc., Emergent Biosolutions Inc., Ichor Medical Systems Inc., Ology Bioservices Inc., SIGA Technologies, Inc., etc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at